Eulerpool/
Stock/
Genmab A/S/
Net Debt

Genmab A/S Net Debt

GMAB.CO

The Net Debt of Genmab A/S (GMAB.CO) as of Jul 30, 2026 is 3.71 B USD. In the previous year, Net Debt was -2.79 B USD — a change of -233.16% (higher).

Get this data via API

Financial Data API

Net Debt

3.71 BUSD

YoY

-233.16%

Last updated: Jul 30, 2026

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

Net Debt of Genmab A/S is 2026 3.71 B USD. Net Debt of Genmab A/S was 2025 -2.79 B USD. It decreases by -233.16% higher compared to the previous year.

Genmab A/S Debt Genmab A/S Cash & Equivalents Genmab A/S Net Debt / EBITDA Genmab A/S Debt-to-Equity

Access this data via the Eulerpool API

Docs Get Free API Key

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Net Debt of Genmab A/S is 3.71 B USD in 2026.

Net Debt of Genmab A/S changed from -2.79 B USD to 3.71 B USD, representing a -233.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Docs Get Free API Key